A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Recruiting · Phase 1, Phase 2 · NCT04752774
Conditions: Spasticity
At a glance
- Research payments reported, 2025
- $12,805
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 240
About the trial
- Sponsor
- Ipsen
- Tested
- Corabotase (biological), Placebo (drug), Dysport (biological)
- Dates
- Started 2021-04-29; completion 2029-03-30
- Results posted
- Not yet
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total Corabotase doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
From ClinicalTrials.gov, last updated 2026-07-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Innovation reported $12,805 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ziyad Ayyoub, M.D. Physical Medicine & Rehabilitation (PM&R) · Paramount, CA
- Atul T. Patel, M.D. Physical Medicine & Rehabilitation (PM&R) · Overland Park, KS
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rancho Research Institute $8,005
- Kansas Institute of Research $4,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.